CHAMPION PHOENIX Trial CHAMPION PHOENIX Trial. N Engl J Med 2013;368:1303–1313. by Nair, Tiny
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 2 9e6 3 56303. Armstrong PW, Gershlick AH, Goldstein P, et al., 2013.
Fibrinolysis or primary PCI in ST-segment elevation
myocardial infarction. N Engl J Med. 368: 1379e1387.
Contributed by
Sundeep Mishra
Sunil Verma
Department of Cardiology, AIIMS, New Delhi, India
E-mail address: drsundeepmishra@hotmail.com (S. Mishra)CHAMPION PHOENIX Trial. N Engl J Med 2013;368:1303e1313.
Objective: The purpose of the study was to investigate the
efficacy and safety of an intravenous ADP antagonist cangre-
lor, in the management of ischemic heart disease patients
going for PCI.
Background: Oral P2Y12 antagonist, clopidogrel has prob-
lems of slow onset of action and erratic absorption, difficulty
in administering to patients unable to swallow (intubated,
drowsy, sedated). Its long duration of action makes it more
prone to cause increased risk of bleeding, especially in emer-
gent CABG situations. Cangrelor, a new intravenous agent is
likely to be safer and efficacious in these respects.
Methods: The study was planned in 153 centers in 12
countries, randomizing 10,900 patients of Stable Angina, NSTE
ACS or STEMI, who were planned for PCI. Patients were
randomized in a double blind, double dummy manner.
Patients were randomized to either IV cangrelor or oral clo-
pidogrel 600 mg or 300 mg followed by maintenance dose
clopidogrel.
The primary efficacy endpoint (PEP) was death, myocardial
infarction (MI), Ischemia Driven Revascularization (IDR), and
stent thrombosis (ST) at 48 h as well as 30 days. The secondary
end points included individual components of the PEP as well
as stent thrombosis. Safety endpoint was GUSTO severe
bleeding at 48 h.
Results: The PEP was seen in 4.7% in cangrelor group while
5.9% in clopidogrel group OR 0.78 (0.66e0.93) p ¼ 0.005. Stent
thrombosis was 0.8% in cangrelor group while 1.4% in clopi-
dogrel group OR 0.62 (0.43e0.90) p ¼ 0.01. There was no dif-
ference in IDR, death or cardiac death. At 30 days, the benefits
of cangrelor persisted with PEP 0.85 (0.73e0.99) p ¼ 0.03; and
ST 0.68 (0.50e0.92) p ¼ 0.01.
Therewas no significant increase in GUSTOmajor bleeding
with cangrelor OR 1.5 (0.53e4.22) p ¼ 0.44 NS.
Conclusion: Intravenously administered cangrelor reduced
primary efficacy end point of death, MI, IDR, ST in a variety of
CAD patients (Stable angina, NSTEMI ACS, STEMI) by 22% in
the background of PCI compared to clopidogrel loading. This
benefit persisted over 30 days follow up. The SEP of ST was
also reduced by 38%. There was no substantial increase in
GUSTO major bleeding.1. Clinical perspective
Most new antiplatelets improve ischemic outcome at the cost
of increased bleeding. Also oral agents have a slow onset ofaction despite loading dose. Oral loading becomes a problem
when the patient is intubated, drowsy, or in shock and is
unable to take orally. The slow onset exposes the patient to a
higher ischemic event risk during PCI. Most oral agents have a
long half-life and a slow dissociation leading to increased
bleeding risk especially when considering a patient needing
emergent CABG.
Cangrelor an intravenous ADP antagonist with a short half-
life has a theoretical advantage of ‘quick inequick out’ met-
abolic profile. In this trial cangrelor showed efficacy better
than clopidogrel (PEP reduced by 22%) and stent thrombosis
reduced by 38%, the benefits persisting at 30 days follow up. At
the same time no increase in GUSTO major bleed was noted.
In this regard cangrelor joins the elite band of bivalirudin,
fondaparinux and ticagrelor which improve ischemic out-
come without compromising on safety.
Administration of cangrelor in the background of new
antiplatelets including prasugrel and ticagrelor (as loading) is
unknown. Also post cangrelor loading, which antiplatelet
would work the best as a maintenance agent is yet to be
decided. This trial confirms the hypothesis that a short acting
intravenous antiplatelet agent is safe and efficacious in the
most crucial first 48 h, persisting upto 30 days.
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M. Packer, W. Colucci, L. Fisher, et al.for the REVIVE Heart
Failure StudyGroup, Effect of levosimendanon the short-term
clinical course of patients with acutely decompensated heart
failure. J Am Coll Cardiol HF 1 (2013) 103e111.Objectives: The purpose of this study was to evaluate the
efficacy and safety of levosimendan, given intravenously to
patients with acutely decompensated heart failure (ADHF).
Background: Levosimendan, a positive inotropic drug with
vasodilator effects has been reported to produce favorable
effects on cardiac performance, symptoms, hospital stays and
survival in patients with ADHF. The hemodynamic effects of
levosimendan persist for many days after a 24 h infusion, due
to a long-lived active metabolite. However, it is not clear that
these hemodynamic effects translate into clinical benefits and
improved outcomes.
Methods: Two sequential trials were performed, the first to
develop a new measure of efficacy in 100 patients, and the
second to use this measure to evaluate levosimendan in an
additional 600 patients. Patients admitted with ADHF received
placebo or intravenous infusion of levosimendan for 24 h in
addition to standard treatment. The primary endpoint was a
composite that evaluated changes in clinical status during the
first 5 days after randomization.
Results: In the 600-patient trial, more levosimendan than
placebo patients improved at all 3 pre-specified time points
(6 h, 24 h, and 5 days), whereas fewer levosimendan
patients experienced clinical worsening (p ¼ 0.015). These
differences were apparent, despite more frequent
